Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AMAROTCMKTS:BETRFOTCMKTS:CPMDNASDAQ:INSYNASDAQ:TLGT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMARAmarillo Biosciences$0.00$0.05▼$1.97$25.24M-0.0618,253 shs6,100 shsBETRFBetterLife Pharma$0.06-10.8%$0.07$0.05▼$0.15$7.51M1.4511,613 shs750 shsCPMDGolden Dragon$0.00$0.00$0.00▼$0.01$2.58M2.43130,066 shs174,312 shsINSYINSYS Therapeutics$23,687,640.18$0.14▼$11.65$21.71M3.219.52 million shsN/ATLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMARAmarillo Biosciences0.00%0.00%0.00%0.00%0.00%BETRFBetterLife Pharma0.00%-4.45%-10.63%+5.45%-35.98%CPMDGolden Dragon0.00%0.00%-11.36%-15.22%-64.55%INSYINSYS Therapeutics0.00%0.00%0.00%0.00%0.00%TLGTTeligent0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMARAmarillo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ABETRFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/ACPMDGolden DragonN/AN/AN/AN/AN/AN/AN/AN/AINSYINSYS TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMARAmarillo Biosciences 0.00N/AN/AN/ABETRFBetterLife Pharma 0.00N/AN/AN/ACPMDGolden Dragon 0.00N/AN/AN/AINSYINSYS Therapeutics 0.00N/AN/AN/ATLGTTeligent 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMARAmarillo Biosciences$20K0.00N/AN/A($0.03) per share0.00BETRFBetterLife PharmaN/AN/AN/AN/A($0.04) per shareN/ACPMDGolden Dragon$820K3.14N/AN/A($0.03) per share-0.13INSYINSYS Therapeutics$82.08M0.00N/AN/A($0.58) per share0.00TLGTTeligentN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMARAmarillo Biosciences-$1.45MN/A0.00N/AN/A-41,453.98%N/A-574.29%N/ABETRFBetterLife Pharma-$2.55M-$0.01N/A∞N/AN/AN/A-609.07%9/23/2025 (Estimated)CPMDGolden Dragon-$9.91M-$0.02N/A∞N/AN/AN/A-56.69%N/AINSYINSYS Therapeutics-$124.51M-$1.39N/AN/AN/A-346.61%-1,430.37%-64.04%N/ATLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest INSY, AMAR, CPMD, TLGT, and BETRF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/10/2025Q4 2024CPMDGolden DragonN/A-$0.01N/A-$0.01N/A$0.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMARAmarillo BiosciencesN/AN/AN/AN/AN/ABETRFBetterLife PharmaN/AN/AN/AN/AN/ACPMDGolden DragonN/AN/AN/AN/AN/AINSYINSYS TherapeuticsN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMARAmarillo BiosciencesN/A0.030.07BETRFBetterLife PharmaN/A0.040.03CPMDGolden DragonN/A0.050.01INSYINSYS TherapeuticsN/A0.540.50TLGTTeligentN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMARAmarillo BiosciencesN/ABETRFBetterLife Pharma0.01%CPMDGolden DragonN/AINSYINSYS Therapeutics14.93%TLGTTeligentN/AInsider OwnershipCompanyInsider OwnershipAMARAmarillo Biosciences34.35%BETRFBetterLife Pharma34.77%CPMDGolden Dragon1.27%INSYINSYS Therapeutics65.40%TLGTTeligent0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMARAmarillo Biosciences242.07 millionN/ANot OptionableBETRFBetterLife Pharma7129.46 million84.45 millionNot OptionableCPMDGolden Dragon4660.63 million652.24 millionNot OptionableINSYINSYS Therapeutics22674.57 millionN/AOptionableTLGTTeligent2,357N/AN/AOptionableINSY, AMAR, CPMD, TLGT, and BETRF HeadlinesRecent News About These CompaniesPAC Profile: TeligentSeptember 11, 2024 | opensecrets.orgOTopical pain reliever recalled for problem that can cause ‘severe morbidity, even death’June 7, 2023 | charlotteobserver.comCβ1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzzMay 13, 2023 | news.google.comNLidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan NewsMay 13, 2023 | news.google.comNGlobal Mobile Value-Added Services (VAS) Industry Market Report ... - Industry TodayMay 11, 2023 | news.google.comNGlobal Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNDry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPRMay 8, 2023 | news.google.comNMobile Value-Added Services (VAS) Market Size, Growth ... - Digital JournalMay 8, 2023 | news.google.comNMobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern ExaminerMay 5, 2023 | news.google.comNEpinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital JournalMay 3, 2023 | news.google.comNErythromycin Market with Focus on Growth Analysis, Production ... - Digital JournalMay 2, 2023 | news.google.comNFrom 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital JournalApril 29, 2023 | news.google.comNTremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPRApril 28, 2023 | news.google.comNDrugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPRApril 26, 2023 | news.google.comNTopical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPRApril 26, 2023 | news.google.comNTriamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan NewsApril 24, 2023 | news.google.comNIDT Corp. Cl BApril 23, 2023 | wsj.comMobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital JournalApril 17, 2023 | news.google.comNHikma Names Injectables Chief Mishlawi As CEO - Generics BulletinApril 12, 2023 | news.google.comNMobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital JournalApril 10, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINSY, AMAR, CPMD, TLGT, and BETRF Company DescriptionsAmarillo Biosciences OTCMKTS:AMARAmarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.BetterLife Pharma OTCMKTS:BETRF$0.06 -0.01 (-10.77%) As of 07/3/2025 12:34 PM EasternBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.Golden Dragon OTCMKTS:CPMD$0.0039 0.00 (0.00%) As of 07/3/2025 11:42 AM EasternCannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.INSYS Therapeutics NASDAQ:INSYInsys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.Teligent NASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
